Into the eye of the cytokine storm

Microbiology and Molecular Biology Reviews

Volumn 76, Issue 1, 2012, Pages 16-32

  Tisoncik, Jennifer R ^a   Korth, Marcus J ^a   Simmons, Cameron P ^b   Farrar, Jeremy ^b   Martin, Thomas R ^c   Katze, Michael G ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b OXFORD UNIVERSITY CLINICAL RESEARCH UNIT   (Viet Nam)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE;

CYTOKINE STORM; GENE EXPRESSION; GENOMICS; HUMAN; IMMUNOMODULATION; REVIEW; SIGNAL TRANSDUCTION; VIRUS INFECTION;

ANIMALS; COMMUNICABLE DISEASES; CYTOKINES; HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; SIGNAL TRANSDUCTION;

AVES; ORTHOMYXOVIRIDAE;

EID: 84860523111     PISSN: 10922172     EISSN: 10985557     Source Type: Journal    
DOI: 10.1128/MMBR.05015-11     Document Type: Review

References (158)

1. Abraham E, et al. 1997. p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group. JAMA 277:1531-1538. (Pubitemid 27213302)
2. Aggarwal BB. 2003. Signalling pathways of the TNF superfamily: a double-edged sword. Nat. Rev. Immunol. 3:745-756. (Pubitemid 41070815)
3. Alberts R, et al. 2010. Gene expression changes in the host response between resistant and susceptible inbred mouse strains after influenza A infection. Microbes Infect. 12:309-318.
4. Arnold R, Neumann M, Konig W. 2007. Peroxisome proliferator-activated receptor-gamma agonists inhibit respiratory syncytial virusinduced expression of intercellular adhesion molecule-1 in human lung epithelial cells. Immunology 121:71-81. (Pubitemid 46537665)
5. Aylor DL, et al. 2011. Genetic analysis of complex traits in the emerging collaborative cross. Genome Res. 21:1213-1222.
6. Barry SM, Johnson MA, Janossy G. 2000. Cytopathology or immunopathology? The puzzle of cytomegalovirus pneumonitis revisited. Bone Marrow Transplant. 26:591-597.
7. Baskin CR, et al. 2009. Early and sustained innate immune response defines pathology and death in nonhuman primates infected by highly pathogenic influenza virus. Proc. Natl. Acad. Sci. U. S. A. 106:3455-3460.
8. Bassaganya-Riera J, Song R, Roberts PC, Hontecillas R. 2010. PPAR-gamma activation as an anti-inflammatory therapy for respiratory virus infections. Viral Immunol. 23:343-352.
9. Bate R, Coticelli P, Tren R, Attaran A. 2008. Antimalarial drug quality in the most severely malarious parts of Africa - a six country study. PLoS One 3:e2132.
10. Becerra A, et al. 2009. Gene expression profiling of dengue infected human primary cells identifies secreted mediators in vivo. J. Med. Virol. 81:1403-1411.
11. Belisle SE, et al. 2010. Genomic profiling of tumor necrosis factor alpha (TNF-alpha) receptor and interleukin-1 receptor knockout mice reveals a link between TNF-alpha signaling and increased severity of 1918 pandemic influenza virus infection. J. Virol. 84:12576-12588.
12. Bensinger SJ, Tontonoz P. 2008. Integration of metabolism and inflammation by lipid-activated nuclear receptors. Nature 454:470-477.
13. Bethell DB, et al. 1998. Pathophysiologic and prognostic role of cytokines in dengue hemorrhagic fever. J. Infect. Dis. 177:778-782. (Pubitemid 28099898)
14. Beutler B, Milsark IW, Cerami AC. 1985. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 229:869-871. (Pubitemid 16246587)
15. Bisno AL, Brito MO, Collins CM. 2003. Molecular basis of group A streptococcal virulence. Lancet Infect. Dis. 3:191-200. (Pubitemid 36389182)
16. Boon AC, et al. 2011. H5N1 influenza virus pathogenesis in genetically diverse mice is mediated at the level of viral load. mBio 2(5):e00171-11.
17. Borden EC, et al. 2007. Interferons at age 50: past, current and future impact on biomedicine. Nat. Rev. Drug Discov. 6:975-990. (Pubitemid 350201788)
18. Brocker C, Thompson D, Matsumoto A, Nebert DW, Vasiliou V. 2010. Evolutionary divergence and functions of the human interleukin (IL) gene family. Hum. Genomics 5:30-55.
19. Brun-Buisson C, Richard JC, Mercat A, Thiebaut AC, Brochard L. 2011. Early corticosteroids in severe influenza A/H1N1 pneumonia and acute respiratory distress syndrome. Am. J. Respir. Crit. Care Med. 183: 1200-1206.
20. Budd A, et al. 2007. Increased survival after gemfibrozil treatment of severe mouse influenza. Antimicrob. Agents Chemother. 51:2965-2968. (Pubitemid 47206237)
21. Cameron MJ, et al. 2007. Interferon-mediated immunopathological events are associated with atypical innate and adaptive immune responses in patients with severe acute respiratory syndrome. J. Virol. 81: 8692-8706. (Pubitemid 47242843)
22. Carey MA, et al. 2010. Pharmacologic inhibition of COX-1 and COX-2 in influenza A viral infection in mice. PLoS One 5:e11610.
23. Carswell EA, et al. 1975. An endotoxin-induced serum factor that causes necrosis of tumors. Proc. Natl. Acad. Sci. U. S. A. 72:3666-3670.
24. Chan MC, et al. 2005. Proinflammatory cytokine responses induced by influenza A (H5N1) viruses in primary human alveolar and bronchial epithelial cells. Respir. Res. 6:135.
25. Chen IY, et al. 2010. Upregulation of the chemokine (C-C motif) ligand 2 via a severe acute respiratory syndrome coronavirus spike-ACE2 signaling pathway. J. Virol. 84:7703-7712.
26. Cheung CY, et al. 2002. Induction of proinflammatory cytokines in human macrophages by influenza A (H5N1) viruses: a mechanism for the unusual severity of human disease? Lancet 360:1831-1837. (Pubitemid 35449422)
27. Cilloniz C, et al. 2010. Lethal dissemination of H5N1 influenza virus is associated with dysregulation of inflammation and lipoxin signaling in a mouse model of infection. J. Virol. 84:7613-7624.
28. Cilloniz C, et al. 2009. Lethal influenza virus infection in macaques is associated with early dysregulation of inflammatory related genes. PLoS Pathog. 5:e1000604.
29. Clark IA. 2007. The advent of the cytokine storm. Immunol. Cell Biol. 85:271-273. (Pubitemid 46878938)
30. Clark IA. 2007. How TNF was recognized as a key mechanism of disease. Cytokine Growth Factor Rev. 18:335-343. (Pubitemid 46891287)
31. Clark IA, Virelizier JL, Carswell EA, Wood PR. 1981. Possible importance of macrophage-derived mediators in acute malaria. Infect. Immun. 32:1058-1066. (Pubitemid 11109808)
32. Cohen J. 2002. The immunopathogenesis of sepsis. Nature 420:885-891. (Pubitemid 36019643)
33. Comerford I, McColl SR. 2011. Focus on chemokines. Immunol. Cell Biol. 89:183-184.
34. Coornaert B, Carpentier I, Beyaert R. 2009. A20: central gatekeeper in inflammation and immunity. J. Biol. Chem. 284:8217-8221.
35. Crowe CR, et al. 2009. Critical role of IL-17RA in immunopathology of influenza infection. J. Immunol. 183:5301-5310.
36. Culley FJ, et al. 2006. Role of CCL5 (RANTES) in viral lung disease. J. Virol. 80:8151-8157. (Pubitemid 44182315)
37. Danesh A, et al. 2011. Early gene expression events in ferrets in response to SARS coronavirus infection versus direct interferon-alpha2b stimulation. Virology 409:102-112.
38. de Jong MD, et al. 2006. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat. Med. 12: 1203-1207.
39. Dessing MC, van der Sluijs KF, Florquin S, van der Poll T. 2007. Monocyte chemoattractant protein 1 contributes to an adequate immune response in influenza pneumonia. Clin. Immunol. 125:328-336. (Pubitemid 350116710)
40. Dinarello C, et al. 2010. IL-1 family nomenclature. Nat. Immunol. 11:973.
41. Dinarello CA. 2009. Immunological and inflammatory functions of the interleukin-1 family. Annu. Rev. Immunol. 27:519-550.
42. Docke WD, et al. 1997. Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. Nat. Med. 3:678-681.
43. Dondorp AM, et al. 2009. Artemisinin resistance in Plasmodium falciparum malaria. N. Engl. J. Med. 361:455-467.
44. Dung NT, et al. 2010. Timing of CD8+ T cell responses in relation to commencement of capillary leakage in children with dengue. J. Immunol. 184:7281-7287.
45. Fensterl V, Sen GC. 2009. Interferons and viral infections. Biofactors 35:14-20.
46. Ferrara JL. 1993. Cytokine dysregulation as a mechanism of graft versus host disease. Curr. Opin. Immunol. 5:794-799. (Pubitemid 23300140)
47. Ferrara JL, Abhyankar S, Gilliland DG. 1993. Cytokine storm of graft-versus-host disease: a critical effector role for interleukin-1. Transplant. Proc. 25:1216-1217. (Pubitemid 23078962)
48. Finck-Barbancon V, et al. 1997. ExoU expression by Pseudomonas aeruginosa correlates with acute cytotoxicity and epithelial injury. Mol. Microbiol. 25:547-557. (Pubitemid 27373583)
49. Fowler AA, Fisher BJ, Centor RM, Carchman RA. 1984. Development of the adult respiratory distress syndrome: progressive alteration of neutrophil chemotactic and secretory processes. Am. J. Pathol. 116:427-435. (Pubitemid 14034009)
50. Franklin BS, et al. 2009. Malaria primes the innate immune response due to interferon-gamma induced enhancement of toll-like receptor expression and function. Proc. Natl. Acad. Sci. U. S. A. 106:5789-5794.
51. Friedman RM. 2008. Clinical uses of interferons. Br. J. Clin. Pharmacol. 65:158-162. (Pubitemid 351171276)
52. Frieman MB, et al. 2010. SARS-CoV pathogenesis is regulated by a STAT1 dependent but a type I, II and III interferon receptor independent mechanism. PLoS Pathog. 6:e1000849.
53. Gabay C, Kushner I. 1999. Acute-phase proteins and other systemic responses to inflammation. N. Engl. J. Med. 340:448-454. (Pubitemid 29084777)
54. Garin A, Proudfoot AE. 2011. Chemokines as targets for therapy. Exp. Cell Res. 317:602-612.
55. Ge D, et al. 2009. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461:399-401.
56. Groom JR, Luster AD. 2011. CXCR3 ligands: redundant, collaborative and antagonistic functions. Immunol. Cell Biol. 89:207-215.
57. Guarda G, et al. 2011. Type I interferon inhibits interleukin-1 production and inflammasome activation. Immunity 34:213-223.
58. Hamilton JA. 2008. Colony-stimulating factors in inflammation and autoimmunity. Nat. Rev. Immunol. 8:533-544. (Pubitemid 351913679)
59. Hinder F, et al. 1991. Influenza A virus infects macrophages and stimulates release of tumor necrosis factor-alpha. Pathobiology 59:227-231.
60. Hoang LT, et al. 2010. The early whole-blood transcriptional signature of dengue virus and features associated with progression to dengue shock syndrome in Vietnamese children and young adults. J. Virol. 84:12982-12994.
61. Holt PG, Strickland DH, Wikstrom ME, Jahnsen FL. 2008. Regulation of immunological homeostasis in the respiratory tract. Nat. Rev. Immunol. 8:142-152. (Pubitemid 351161302)
62. Houde M, Arora DJ. 1990. Stimulation of tumor necrosis factor secretion by purified influenza virus neuraminidase. Cell. Immunol. 129:104- 111.
63. Huang KJ, et al. 2005. An interferon-gamma-related cytokine storm in SARS patients. J. Med. Virol. 75:185-194.
64. Humphreys IR, et al. 2003. OX40 ligation on activated T cells enhances the control of Cryptococcus neoformans and reduces pulmonary eosinophilia. J. Immunol. 170:6125-6132. (Pubitemid 36682595)
65. Humphreys IR, et al. 2003. A critical role for OX40 in T cell-mediated immunopathology during lung viral infection. J. Exp. Med. 198:1237-1242. (Pubitemid 37323388)
66. Hussell T, Goulding J. 2010. Structured regulation of inflammation during respiratory viral infection. Lancet Infect. Dis. 10:360-366.
67. Hussell T, Pennycook A, Openshaw PJ. 2001. Inhibition of tumor necrosis factor reduces the severity of virus-specific lung immunopathology. Eur. J. Immunol. 31:2566-2573. (Pubitemid 32898723)
68. Imai Y, et al. 2008. Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell 133:235-249. (Pubitemid 351512299)
69. Imai Y, et al. 2003. Injurious mechanical ventilation and end-organ epithelial cell apoptosis and organ dysfunction in an experimental model of acute respiratory distress syndrome. JAMA 289:2104-2112. (Pubitemid 37430212)
70. Imashuku S. 2002. Clinical features and treatment strategies of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. Crit. Rev. Oncol. Hematol. 44:259-272. (Pubitemid 35435291)
71. Jahrling PB, et al. 2004. Exploring the potential of variola virus infection of cynomolgus macaques as a model for human smallpox. Proc. Natl. Acad. Sci. U. S. A. 101:15196-15200. (Pubitemid 39391741)
72. Jiang D, et al. 2005. Regulation of lung injury and repair by Toll-like receptors and hyaluronan. Nat. Med. 11:1173-1179. (Pubitemid 43093664)
73. Kash JC, et al. 2006. Genomic analysis of increased host immune and cell death responses induced by 1918 influenza virus. Nature 443:578-581. (Pubitemid 44527293)
74. Kato H, et al. 2005. Cell type-specific involvement of RIG-I in antiviral response. Immunity 23:19-28. (Pubitemid 41019654)
75. Katze MG, Fornek JL, Palermo RE, Walters KA, Korth MJ. 2008. Innate immune modulation by RNA viruses: emerging insights from functional genomics. Nat. Rev. Immunol. 8:644-654.
76. Kawai T, et al. 2005. IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction. Nat. Immunol. 6:981-988. (Pubitemid 41486182)
77. Khor CC, et al. 2010. CISH and susceptibility to infectious diseases. N. Engl. J. Med. 362:2092-2101.
78. Kobasa D, et al. 2007. Aberrant innate immune response in lethal infection of macaques with the 1918 influenza virus. Nature 445:319-323. (Pubitemid 46122819)
79. Kopf M, Bachmann MF, Marsland BJ. 2010. Averting inflammation by targeting the cytokine environment. Nat. Rev. Drug Discov. 9:703-718.
80. Kurahashi K, et al. 1999. Pathogenesis of septic shock in Pseudomonas aeruginosa pneumonia. J. Clin. Invest. 104:743-750. (Pubitemid 29536359)
81. La Gruta NL, Kedzierska K, Stambas J, Doherty PC. 2007. A question of self-preservation: immunopathology in influenza virus infection. Immunol. Cell Biol. 85:85-92. (Pubitemid 46398724)
82. Lee SM, et al. 2010. Systems-level comparison of host responses induced by pandemic and seasonal influenza A H1N1 viruses in primary human type I-like alveolar epithelial cells in vitro. Respir. Res. 11:147.
83. Lee SM, et al. 2008. Hyperinduction of cyclooxygenase-2-mediated proinflammatory cascade: a mechanism for the pathogenesis of avian influenza H5N1 infection. J. Infect. Dis. 198:525-535.
84. Levy MM, et al. 2003. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit. Care Med. 31:1250-1256. (Pubitemid 36444440)
85. Li C, et al. 2011. Host regulatory network response to infection with highly pathogenic H5N1 avian influenza virus. J. Virol. 85:10955-10967.
86. Libraty DH, et al. 2002. Differing influences of virus burden and immune activation on disease severity in secondary dengue-3 virus infections. J. Infect. Dis. 185:1213-1221. (Pubitemid 34439127)
87. Lin KL, Suzuki Y, Nakano H, Ramsburg E, Gunn MD. 2008. CCR2+ monocyte-derived dendritic cells and exudate macrophages produce influenza-induced pulmonary immune pathology and mortality. J. Immunol. 180:2562-2572.
88. Lin KL, Sweeney S, Kang BD, Ramsburg E, Gunn MD. 2011. CCR2-antagonist prophylaxis reduces pulmonary immune pathology and markedly improves survival during influenza infection. J. Immunol. 186: 508-515.
89. Link H. 1998. The cytokine storm in multiple sclerosis. Mult. Scler. 4:12-15. (Pubitemid 28077430)
90. Long HT, et al. 2009. Patterns of gene transcript abundance in the blood of children with severe or uncomplicated dengue highlight differences in disease evolution and host response to dengue virus infection. J. Infect. Dis. 199:537-546.
91. Loo YM, et al. 2008. Distinct RIG-I and MDA5 signaling by RNA viruses in innate immunity. J. Virol. 82:335-345.
92. Loo YM, Gale M, Jr. 2011. Immune signaling by RIG-I-like receptors. Immunity 34:680-692.
93. Ma W, et al. 2011. 2009 pandemic H1N1 virus causes disease and upregulation of genes related to inflammatory and immune response, cell death and lipid metabolism in pigs. J. Virol. 85:11626-11637.
94. Makhija R, Kingsnorth AN. 2002. Cytokine storm in acute pancreatitis. J. Hepatobil. Pancreat. Surg. 9:401-410. (Pubitemid 36305074)
95. Marsolais D, et al. 2009. A critical role for the sphingosine analog AAL-R in dampening the cytokine response during influenza virus infection. Proc. Natl. Acad. Sci. U. S. A. 106:1560-1565.
96. Matute-Bello G, Frevert CW, Martin TR. 2008. Animal models of acute lung injury. Am. J. Physiol. Lung Cell. Mol. Physiol. 295:L379-L399.
97. McDermott JE, et al. 2011. Conserved host response to highly pathogenic avian influenza virus infection in human cell culture, mouse and macaque model systems. BMC Syst. Biol. 5:190.
98. Meijvis SC, et al. 2011. Dexamethasone and length of hospital stay in patients with community-acquired pneumonia: a randomised, double-blind, placebo-controlled trial. Lancet 377:2023-2030.
99. Michel O, et al. 2003. Systemic responsiveness to lipopolysaccharide and polymorphisms in the Toll-like receptor 4 gene in human beings. J. Allergy Clin. Immunol. 112:923-929. (Pubitemid 37412060)
100. Mockenhaupt FP, et al. 2006. Toll-like receptor (TLR) polymorphisms in African children: common TLR-4 variants predispose to severe malaria. Proc. Natl. Acad. Sci. U. S. A. 103:177-182. (Pubitemid 43076124)
101. Mockenhaupt FP, et al. 2006. Common polymorphisms of Toll-like receptors 4 and 9 are associated with the clinical manifestation of malaria during pregnancy. J. Infect. Dis. 194:184-188. (Pubitemid 44087189)
102. Mongkolsapaya J, et al. 2003. Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. Nat. Med. 9:921-927. (Pubitemid 36889936)
103. Monick MM, et al. 2003. Respiratory syncytial virus up-regulates TLR4 and sensitizes airway epithelial cells to endotoxin. J. Biol. Chem. 278: 53035-53044. (Pubitemid 38035906)
104. Monneret G, et al. 2006. Persisting low monocyte human leukocyte antigen-DR expression predicts mortality in septic shock. Intensive Care Med. 32:1175-1183. (Pubitemid 44232412)
105. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. 2001. Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol. 19:683-765. (Pubitemid 32368050)
106. Mordstein M, et al. 2008. Interferon-lambda contributes to innate immunity of mice against influenza A virus but not against hepatotropic viruses. PLoS Pathog. 4:e1000151.
107. Moyron-Quiroz JE, et al. 2004. Role of inducible bronchus associated lymphoid tissue (iBALT) in respiratory immunity. Nat. Med. 10:927-934. (Pubitemid 39273733)
108. Munford RS, Pugin J. 2001. Normal responses to injury prevent systemic inflammation and can be immunosuppressive. Am. J. Respir. Crit. Care Med. 163:316-321. (Pubitemid 32158505)
109. Nawroth PP, et al. 1986. Tumor necrosis factor/cachectin interacts with endothelial cell receptors to induce release of interleukin 1. J. Exp. Med. 163:1363-1375. (Pubitemid 16043458)
110. Oshiumi H, Matsumoto M, Funami K, Akazawa T, Seya T. 2003. TICAM-1, an adaptor molecule that participates in Toll-like receptor 3-mediated interferon-beta induction. Nat. Immunol. 4:161-167. (Pubitemid 36193018)
111. Osterlund P, et al. 2010. Pandemic H1N1 2009 influenza A virus induces weak cytokine responses in human macrophages and dendritic cells and is highly sensitive to the antiviral actions of interferons. J. Virol. 84:1414-1422.
112. Pankhaniya RR, et al. 2004. Pseudomonas aeruginosa causes acute lung injury via the catalytic activity of the patatin-like phospholipase domain of ExoU. Crit. Care Med. 32:2293-2299. (Pubitemid 39491811)
113. Park WY, et al. 2001. Cytokine balance in the lungs of patients with acute respiratory distress syndrome. Am. J. Respir. Crit. Care Med. 164: 1896-1903. (Pubitemid 33152327)
114. Peiris JS, Cheung CY, Leung CY, Nicholls JM. 2009. Innate immune responses to influenza A H5N1: friend or foe? Trends Immunol. 30:574-584.
115. Peiris JS, Hui KP, Yen HL. 2010. Host response to influenza virus: protection versus immunopathology. Curr. Opin. Immunol. 22:475-481.
116. Peiris JS, et al. 2004. Re-emergence of fatal human influenza A subtype H5N1 disease. Lancet 363:617-619. (Pubitemid 38264181)
117. Perrone LA, Szretter KJ, Katz JM, Mizgerd JP, Tumpey TM. 2010. Mice lacking both TNF and IL-1 receptors exhibit reduced lung inflammation and delay in onset of death following infection with a highly virulent H5N1 virus. J. Infect. Dis. 202:1161-1170.
118. Pugin J, Ricou B, Steinberg KP, Suter PM, Martin TR. 1996. Proinflammatory activity in bronchoalveolar lavage fluids from patients with ARDS, a prominent role for interleukin-1. Am. J. Respir. Crit. Care Med. 153:1850-1856. (Pubitemid 26187910)
119. Raman D, Sobolik-Delmaire T, Richmond A. 2011. Chemokines in health and disease. Exp. Cell Res. 317:575-589.
120. Rivera J, Proia RL, Olivera A. 2008. The alliance of sphingosine-1- phosphate and its receptors in immunity. Nat. Rev. Immunol. 8:753- 763.
121. Rubenfeld GD, et al. 2005. Incidence and outcomes of acute lung injury. N. Engl. J. Med. 353:1685-1693. (Pubitemid 41464707)
122. Sabbah A, et al. 2009. Activation of innate immune antiviral responses by Nod2. Nat. Immunol. 10:1073-1080.
123. Safronetz D, et al. 2011. Pandemic swine-origin H1N1 influenza A virus isolates show heterogeneous virulence in macaques. J. Virol. 85:1214-1223.
124. Schmitz N, Kurrer M, Bachmann MF, Kopf M. 2005. Interleukin-1 is responsible for acute lung immunopathology but increases survival of respiratory influenza virus infection. J. Virol. 79:6441-6448. (Pubitemid 40617247)
125. Seo SH, Webster RG. 2002. Tumor necrosis factor alpha exerts powerful anti-influenza virus effects in lung epithelial cells. J. Virol. 76:1071-1076. (Pubitemid 34066411)
126. Sethi G, Sung B, Kunnumakkara AB, Aggarwal BB. 2009. Targeting TNF for treatment of cancer and autoimmunity. Adv. Exp. Med. Biol. 647:37-51.
127. Sheppard P, et al. 2003. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat. Immunol. 4:63-68. (Pubitemid 36104710)
128. Shinya K, et al. 2006. Avian flu: influenza virus receptors in the human airway. Nature 440:435-436.
129. Simmons C, Farrar J. 2008. Insights into inflammation and influenza. N. Engl. J. Med. 359:1621-1623.
130. Simmons CP, et al. 2007. Patterns of host genome-wide gene transcript abundance in the peripheral blood of patients with acute dengue hemorrhagic fever. J. Infect. Dis. 195:1097-1107. (Pubitemid 46543440)
131. Simmons CP, et al. 2006. Pretreatment intracerebral and peripheral blood immune responses in Vietnamese adults with tuberculous meningitis: diagnostic value and relationship to disease severity and outcome. J. Immunol. 176:2007-2014. (Pubitemid 43134346)
132. Sims JE, Smith DE. 2010. The IL-1 family: regulators of immunity. Nat. Rev. Immunol. 10:89-102.
133. Snelgrove RJ, et al. 2008. A critical function for CD200 in lung immune homeostasis and the severity of influenza infection. Nat. Immunol. 9:1074-1083.
134. Srikiatkhachorn A, et al. 2007. Virus-induced decline in soluble vascular endothelial growth receptor 2 is associated with plasma leakage in dengue hemorrhagic Fever. J. Virol. 81:1592-1600. (Pubitemid 46214434)
135. Sun L, et al. 2011. New concepts of IL-10-induced lung fibrosis: fibrocyte recruitment andM2activation in a CCL2/CCR2 axis. Am. J. Physiol. Lung Cell. Mol. Physiol. 300:L341-L353.
136. Suntharalingam G, et al. 2006. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N. Engl. J. Med. 355:1018-1028. (Pubitemid 44343545)
137. Szretter KJ, et al. 2007. Role of host cytokine responses in the pathogenesis of avian H5N1 influenza viruses in mice. J. Virol. 81:2736-2744. (Pubitemid 46447038)
138. Taveira da Silva AM, et al. 1993. Shock and multiple-organ dysfunction after self-administration of Salmonella endotoxin. N. Engl. J. Med. 328: 1457-1460.
139. Teijaro JR, et al. 2011. Endothelial cells are central orchestrators of cytokine amplification during influenza virus infection. Cell 146:980-991.
140. Thomas DL, et al. 2009. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461:798-801.
141. Tobin DM, et al. 2010. The lta4h locus modulates susceptibility to mycobacterial infection in zebrafish and humans. Cell 140:717-730.
142. Tulic MK, et al. 2007. TLR4 polymorphisms mediate impaired responses to respiratory syncytial virus and lipopolysaccharide. J. Immunol. 179:132-140. (Pubitemid 46986527)
143. van Iersel MP, et al. 2008. Presenting and exploring biological pathways with PathVisio. BMC Bioinformatics 9:399.
144. Viasus D, et al. 2011. Effect of immunomodulatory therapies in patients with pandemic influenza A (H1N1) 2009 complicated by pneumonia. J. Infect. 62:193-199.
145. Wang H, Ma S. 2008. The cytokine storm and factors determining the sequence and severity of organ dysfunction in multiple organ dysfunction syndrome. Am. J. Emerg. Med. 26:711-715. (Pubitemid 351905818)
146. Weingartl HM, et al. 2009. Experimental infection of pigs with the human 1918 pandemic influenza virus. J. Virol. 83:4287-4296.
147. Williams AE, et al. 2005. TGF-beta prevents eosinophilic lung disease but impairs pathogen clearance. Microbes Infect. 7:365-374. (Pubitemid 40603434)
148. Willinger T, et al. 2011. Human IL-3/GM-CSF knock-in mice support human alveolar macrophage development and human immune responses in the lung. Proc. Natl. Acad. Sci. U. S. A. 108:2390-2395.
149. WurfelMM.2008. Genetic insights into sepsis: what have we learned and how will it help? Curr. Pharm. Des. 14:1900-1911.
150. Wurfel MM, et al. 2008. Toll-like receptor 1 polymorphisms affect innate immune responses and outcomes in sepsis. Am. J. Respir. Crit. Care Med. 178:710-720.
151. Wurfel MM, et al. 2005. Identification of high and low responders to lipopolysaccharide in normal subjects: an unbiased approach to identify modulators of innate immunity. J. Immunol. 175:2570-2578. (Pubitemid 41113870)
152. Yamamoto M, et al. 2003. Role of adaptor TRIF in the MyD88-independent Toll-like receptor signaling pathway. Science 301:640-643. (Pubitemid 36927946)
153. Yamamoto M, et al. 2002. A novel Toll/IL-1 receptor domaincontaining adapter that preferentially activates the IFN-beta promoter in the Toll-like receptor signaling. J. Immunol. 169:6668-6672. (Pubitemid 36899248)
154. Yokota S. 2003. Influenza-associated encephalopathy-pathophysiology and disease mechanisms. Nippon Rinsho. 61:1953-1958.
155. Yuen KY, Wong SS. 2005. Human infection by avian influenza A H5N1. Hong Kong Med. J. 11:189-199. (Pubitemid 40826027)
156. Zhang Q, et al. 2010. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature 464:104-107.
157. Zheng BJ, et al. 2008. Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza A/H5N1 virus. Proc. Natl. Acad. Sci. U. S. A. 105:8091-8096.
158. Zornetzer GA, et al. 2010. Transcriptomic analysis reveals a mechanism for a prefibrotic phenotype in STAT1 knockout mice during severe acute respiratory syndrome coronavirus infection. J. Virol. 84:11297-11309.